Phase I study to evaluate safety, tolerability, pharmacokinetics and anti-tumor activity of WSD0922-FU

Medicine & Life Sciences

1. Astrocytoma 100%
2. epidermal growth factor receptor VIII 87%
3. Pharmacokinetics 67%
4. Maximum Tolerated Dose 52%
5. Safety 34%
6. Neoplasms 24%
7. Orphan Drug Production 13%
8. Food 12%
9. Biomarkers 11%
10. RNA Sequence Analysis 10%
11. Feasibility Studies 9%
12. DNA Sequence Analysis 9%
13. Drug Development 8%
14. Proteomics 8%
15. Meals 8%
16. Non-Small Cell Lung Carcinoma 8%
17. Eating 6%
18. Fats 6%
19. Research Personnel 6%
20. Clinical Trials 5%
21. Neoplasm Metastasis 5%
22. Mutation 5%